Anti-Human PD-L1 Reference Antibody (NM-01, RUO) (HV974336)

Name: Anti-Human PD-L1 Reference Antibody (NM-01, RUO)
Brand: abinScience
SKU: HV974336
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HV974336
Description	Anti-Human CD274/PD-L1/B7-H1 (NM-01) (HV974336) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG
ID de clone	NM-01
Cible	B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q9NZQ7
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	NM-01, NM01, NM01
Contexte	Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi). 1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443 2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410 3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417 4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419 5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298 6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077 7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201
Note	For research use only. Not suitable for clinical or therapeutic use.